AC
Collaborations Pharmaceuticals Pipeline
| Drug | Indication | Phase |
|---|---|---|
| CPI-601 (recombinant human PPT1) | CLN1 Batten Disease (Infantile Neuronal Ceroid Lipofuscinosis) | Preclinical |
| Small Molecule PPT1 Inhibitors (e.g., Orlistat, Palmostatin B) | CLN1 Batten Disease (Potential chaperones) | Preclinical |
| 1-Sulfonyl-3-amino-1H-1,2,4-triazoles | Yellow Fever Virus Infection | Preclinical |
| 3-methyltoxoflavin | Chikungunya Virus Infection | Preclinical |
| ML-Discovered Antiviral Compound | Yellow Fever Virus Infection | Preclinical |
Leadership Team at Collaborations Pharmaceuticals
SE
Sean Ekins
Founder, Chief Executive Officer, Board Member
MA
Maggie A.Z. Hupcey
Chief Operating Officer
TL
Thomas Lane
Associate Director
RR
Renuka Raman
Associate Director
JH
Josh Harris
Associate Director
AO
Aaron Oliver
Business Development Manager
PV
Patricia Vignaux
Senior Scientist
CY
Chris Yogodzinski
Staff Scientist
MH
Meena Hamilton
Staff Scientist
TJ
Thane Jones
Staff Scientist